Genetic variants in levodopa-induced dyskinesia (LID): A systematic review and meta-analysis

Tysnes, 2017, Epidemiology of Parkinson's disease, J. Neural. Transm., 124, 901, 10.1007/s00702-017-1686-y Fabbrini, 2007, Levodopa-induced dyskinesias, Mov. Disord., 22, 1379, 10.1002/mds.21475 Wu, 2019, The impact of levodopa therapy-induced complications on quality of life in Parkinson's disease patients in Singapore, Sci. Rep., 9, 9248, 10.1038/s41598-019-45110-5 Bjornestad, 2016, Risk and course of motor complications in a population-based incident Parkinson’s disease cohort, Park. Relat. Disord., 22, 48, 10.1016/j.parkreldis.2015.11.007 Stocchi, 2004, Continuous dopaminergic stimulation in early and advanced Parkinson's disease, Neurology, 62, S56, 10.1212/WNL.62.1_suppl_1.S56 Gilgun-Sherki, 2004, Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson’s disease, Pharmacogenomics J., 4, 291, 10.1038/sj.tpj.6500260 Zappia, 2005, Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study, Arch. Neurol., 62, 601, 10.1001/archneur.62.4.601 Fahn, 1999, Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA, Arch. Neurol., 56, 529, 10.1001/archneur.56.5.529 Linazasoro, 2005, New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity, Trends Pharmacol. Sci., 26, 391, 10.1016/j.tips.2005.06.007 Marconi, 1994, Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology, Mov. Disord. Off. J. Mov. Disord. Soc., 9, 2, 10.1002/mds.870090103 Brotchie, 2005, Nondopaminergic mechanisms in levodopa-induced dyskinesia, Mov. Disord. Off. J. Mov. Disord. Soc., 20, 919, 10.1002/mds.20612 Blankenburg, 2017, A web resource for levodopa-induced dyskinesia genetics in Parkinson's disease, Neuroinformatics, 15, 297, 10.1007/s12021-017-9327-z Moher, 2009, Reprint--preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, Phys. Ther., 89, 873, 10.1093/ptj/89.9.873 Bruford, 2008, The HGNC Database in 2008: a resource for the human genome, Nucleic Acids Res., 36, D445, 10.1093/nar/gkm881 Sherry, 2001, dbSNP: the NCBI database of genetic variation, Nucleic Acids Res., 29, 308, 10.1093/nar/29.1.308 Oliveri, 1999, Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD, Neurology, 53, 1425, 10.1212/WNL.53.7.1425 Comi, 2017, Polymorphisms of dopamine receptor genes and risk of L-dopa-induced dyskinesia in Parkinson's disease, Int. J. Mol. Sci., 18, E242, 10.3390/ijms18020242 Kusters, 2018, Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease, Park. Relat. Disord., 47, 39, 10.1016/j.parkreldis.2017.11.339 Strong, 2006, Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease, Mov. Disord. Off. J. Mov. Disord. Soc., 21, 654, 10.1002/mds.20785 Kaplan, 2014, Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease, J. Mol. Neurosci., 53, 183, 10.1007/s12031-014-0276-9 Rieck, 2012, DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients, Pharmacogenomics, 13, 1701, 10.2217/pgs.12.149 Greenbaum, 2013, Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study, J. Mol. Neurosci., 51, 380, 10.1007/s12031-013-0020-x Kaiser, 2003, L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism, Neurology, 60, 1750, 10.1212/01.WNL.0000068009.32067.A1 Lee, 2011, Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease, Mov. Disord. Off. J. Mov. Disord. Soc., 26, 73, 10.1002/mds.23400 Paus, 2009, Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism, Mov. Disord., 24, 1080, 10.1002/mds.22508 Ivanova, 2012, NMDA receptor genotypes associated with the vulnerability to develop dyskinesia, Transl. Psychiatry, 2, e67, 10.1038/tp.2011.66 Neville, 2004, Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1, Hum. Mutat., 23, 540, 10.1002/humu.20039 Rieck, 2015, Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson's disease patients?, Pharmacogenomics, 16, 573, 10.2217/pgs.15.23 Bond, 1998, Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction, Proc. Natl. Acad. Sci. U.S.A., 95, 9608, 10.1073/pnas.95.16.9608 Vandenbergh, 1992, Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR, Genomics, 14, 1104, 10.1016/S0888-7543(05)80138-7 van Dyck, 2005, Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene, J. Nucl. Med. Off. Publ. Soc. Nucl. Med., 46, 745 Fuke, 2001, The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression, Pharmacogenomics J., 1, 152, 10.1038/sj.tpj.6500026 Purcaro, 2019, DAT gene polymorphisms (rs28363170, rs393795) and levodopa-induced dyskinesias in Parkinson's disease, Neurosci. Lett., 18, 83, 10.1016/j.neulet.2018.10.021 Kurth, 1993, Association of a monoamine oxidase B allele with Parkinson's disease, Ann. Neurol., 33, 368, 10.1002/ana.410330406 Costa-Mallen, 2005, Characterization of the in vitro transcriptional activity of polymorphic alleles of the human monoamine oxidase-B gene, Neurosci. Lett., 383, 171, 10.1016/j.neulet.2005.04.004 Garpenstrand, 2000, Platelet monoamine oxidase activity is related to MAOB intron 13 genotype, J. Neural Transm. Vienna Austria, 107, 523, 10.1007/s007020070075 Hao, 2014, Association of Catechol-O-Methyltransferase and monoamine oxidase B gene polymorphisms with motor complications in Parkinson's disease in a Chinese population, Park. Relat. Disord., 20, 1041, 10.1016/j.parkreldis.2014.06.021 Sampaio, 2018, MAO-B and COMT genetic variations associated with levodopa treatment response in patients with Parkinson's disease, J. Clin. Pharmacol., 58, 920, 10.1002/jcph.1096 Białecka, 2004, The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease, Acta Neurol. Scand., 110, 260, 10.1111/j.1600-0404.2004.00315.x Torkaman-Boutorabi, 2012, The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease, Acta Neurobiol. Exp., 72, 272 Cheshire, 2014, Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease, Neurodegener. Dis., 13, 24, 10.1159/000351097 Lotta, 1995, Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme, Biochemistry (Mosc.), 34, 4202, 10.1021/bi00013a008 Rivera-Calimlim, 1984, Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: difference in levodopa tolerance, Clin. Pharmacol. Ther., 35, 804, 10.1038/clpt.1984.116 de Lau, 2012, Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease, Mov. Disord., 27, 132, 10.1002/mds.23805 Bialecka, 2008, The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications, Pharmacogenetics Genom., 18, 815, 10.1097/FPC.0b013e328306c2f2 Contin, 2005, Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease, Mov. Disord. Off. J. Mov. Disord. Soc., 20, 734, 10.1002/mds.20410 Watanabe, 2003, Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease, Neuropsychobiology, 48, 190, 10.1159/000074637 Monfrini, 2017, Leucine-rich repeat kinase (LRRK2) genetics and Parkinson’s disease, Adv. Neurobiol., 14, 3, 10.1007/978-3-319-49969-7_1 Lesage, 2008, Is the common LRRK2 G2019S mutation related to dyskinesias in North African Parkinson disease?, Neurology, 71, 1550, 10.1212/01.wnl.0000338460.89796.06 Nishioka, 2010, A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease, J. Neurol. Neurosurg. Psychiatry, 81, 391, 10.1136/jnnp.2009.185231 Yahalom, 2012, Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation, Park. Relat. Disord., 18, 1039, 10.1016/j.parkreldis.2012.05.014 Healy, 2008, Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study, Lancet Neurol., 7, 583, 10.1016/S1474-4422(08)70117-0 Thoenen, 1991, The synthesis of nerve growth factor and brain-derived neurotrophic factor in hippocampal and cortical neurons is regulated by specific transmitter systems, Ann. N. Y. Acad. Sci., 640, 86, 10.1111/j.1749-6632.1991.tb00196.x Foltynie, 2009, BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease, J. Neurol. Neurosurg. Psychiatry, 80, 141, 10.1136/jnnp.2008.154294 Schumacher-Schuh, 2014, Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients, Pharmacogenomics J., 14, 289, 10.1038/tpj.2013.37 Molchadski, 2011, The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia, Acta Neurol. Scand., 123, 117, 10.1111/j.1600-0404.2010.01352.x Santos-Lobato, 2018, Association of a neuronal nitric oxide synthase gene polymorphism with levodopa-induced dyskinesia in Parkinson's disease, Nitric Oxide, 74, 86, 10.1016/j.niox.2017.06.004 Lin, 2002, Association between genetic polymorphism of angiotensin-converting enzyme gene and Parkinson's disease, J. Neurol. Sci., 199, 25, 10.1016/S0022-510X(02)00081-3 Turjanski, 1997, In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias, Neurology, 49, 717, 10.1212/WNL.49.3.717 Gordon, 2003, Errors and linkage disequilibrium interact multiplicatively when computing sample sizes for genetic case-control association studies, Pac. Symp. Biocomput., 490 Scherag, 2003, Data adaptive interim modification of sample sizes for candidate-gene association studies, Hum. Hered., 56, 56, 10.1159/000073733 Pfeiffer, 2003, Sample size calculations for population- and family-based case-control association studies on marker genotypes, Genet. Epidemiol., 25, 136, 10.1002/gepi.10245 Ponce, 2009, The ANKK1 kinase gene and psychiatric disorders, Neurotox. Res., 16, 50, 10.1007/s12640-009-9046-9 Calon, 2004, Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias, Brain J. Neurol., 127, 1075, 10.1093/brain/awh128 Bibbiani, 2003, A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease, Exp. Neurol., 184, 285, 10.1016/S0014-4886(03)00250-4 Hauser, 2011, Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial, Lancet Neurol., 10, 221, 10.1016/S1474-4422(11)70012-6 Lundblad, 2003, Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia, J. Neurochem., 84, 1398, 10.1046/j.1471-4159.2003.01632.x Fox, 2018, Movement Disorder Society Evidence-Based Medicine Committee. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease, Mov. Disord., 33, 1248, 10.1002/mds.27372 Kurian, 2011, Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study, Lancet Neurol., 10, 54, 10.1016/S1474-4422(10)70269-6 Hashim, 2014, Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease, Int. J. Neurosci., 124, 187, 10.3109/00207454.2013.833511 Olanow, 2009, Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis, Mov. Disord., 24, 336, 10.1002/mds.22208 Egan, 2003, The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function, Cell, 112, 257, 10.1016/S0092-8674(03)00035-7 Zintzaras, 2008, Trends in meta-analysis of genetic association studies, J. Hum. Genet., 53, 1, 10.1007/s10038-007-0223-5